ReviewInternational journal of hematology2026
Immunological links between aplastic anemia and paroxysmal nocturnal hemoglobinuria.
Review in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH) are closely related bone marrow (BM) failure syndromes linked by shared immunological mechanisms. The frequent emergence of PNH-type blood cells during AA, together with the co-occurrence of the disorders and their overlapping therapeutic responses, supports the concept that they represent a spectrum of immune-mediated hematopoietic injury rather than distinct disease entities.AA is a prototypical immune-mediated BM failure characterized by cytotoxic T-cell-driven suppression of hematopoietic stem and progenitor cells. Within this immune-hostile environment, glycosylphosphatidylinositol (GPI)-anchor-deficient PNH clones commonly emerge and persist, a phenomenon best explained by immune selection rather than intrinsic proliferative advantage. Although most PNH clones detected in AA remain small and clinically silent, their presence reflects ongoing or past immune pressure within the BM microenvironment.Advances in high-sensitivity flow cytometry have revealed that minor PNH populations are frequent in AA, indicating that immune-driven clonal selection occurs at an early stage of hematopoiesis. Longitudinal studies further demonstrate that clonal dynamics parallel changes in immune activity, supporting their relevance for risk-adapted monitoring.In this review, we highlight immune-mediated BM failure as the common soil from which PNH clones arise and discuss implications for diagnosis, monitoring, and phenotype-driven management.
Indexed as
Identifiers
42260206What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.